Smad3-Deficient CD11b+Gr1+ Myeloid-Derived Suppressor Cells Prevent Allograft Rejection via the Nitric Oxide Pathway

Tingting Wu, Chenming Sun, Zhigang Chen, Yu Zhen, Jianxia Peng, Zhongquan Qi, Xiao Yang and Yong Zhao

J Immunol 2012; 189:4989-5000; Prepublished online 8 October 2012;
doi: 10.4049/jimmunol.1200068
http://www.jimmunol.org/content/189/10/4989

Supplementary Material
http://www.jimmunol.org/content/suppl/2012/10/10/jimmunol.1200068.DC1

References
This article cites 61 articles, 21 of which you can access for free at:
http://www.jimmunol.org/content/189/10/4989.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Smad3-Deficient CD11b+Gr1+ Myeloid-Derived Suppressor Cells Prevent Allograft Rejection via the Nitric Oxide Pathway

Tingting Wu,* Chenming Sun,* Zhigang Chen,† Yu Zhen,* Jianxia Peng,* Zhongquan Qi,‡ Xiao Yang,‡ and Yong Zhao*†

Immunosuppressive CD11b+Gr1+ myeloid-derived suppressor cells and TGF-β have been shown to negatively regulate host immunity against allografts. Our results demonstrated that Smad3-deficient mice or mice reconstituted with Smad3-deficient hematopoietic cells rejected allogeneic skin or heart grafts in significantly slower manner compared with littermates or wild-type (WT) control mice. Transplanted Smad3−/− recipients produced markedly less anti-donor IgG Abs, especially IgG1 and IgG2b subclasses. T cells in alloskin-grafted Smad3-deficient mice were more likely to participate in a Th2-type immune response, as evidenced by more Th2-specific transcription factor, GATA3 expression, and increased IL-4 and IL-10 production, as well as less Th1-specific transcription factor, T-bet expression, and decreased IL-2 and IFN-γ production. More CD11b+Gr1+ neutrophil infiltration and less monocyte/macrophage and T cell infiltration in allografts were observed in Smad3−/− recipients compared with WT recipients. Increased CXCL1 and CXCL2 as well as decreased CCL3, MCP-1, and RANTES chemokines in allografts of Smad3−/− recipients were consistently detected by real-time PCR. Further studies indicated that the increased CD11b+Gr1+ myeloid cells in Smad3-deficient mice were immunosuppressive and responsible for the delayed allograft rejection mainly via an NO-dependent pathway. Thus, this study identifies Smad3 as an intrinsic negative regulator that critically inhibits the differentiation and function of immunosuppressive CD11b+Gr1+ myeloid-derived suppressor cells. The Journal of Immunology, 2012, 189: 4989–5000.

R ejection of solid organ allografts is the result of a complex series of interactions between the innate and adaptive immune systems (1, 2). Many aspects of the innate immune response, including cellular infiltration and various chemokines and proinflammatory cytokines, play a critical role in shaping T cell response during the allograft rejection process (3, 4). Recently, CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs), an important regulatory innate cell population, were defined functionally by their immunosuppressive activity in hosts with tumors, transplants, or chronic infections (5, 6). Its immunosuppressive function is mediated through combinations of several major molecular pathways, including the inducible NO synthase (iNOS) pathway (7). Production of NO by iNOS has been shown to block T cell adhesion, differentiation, cytokine production, and proliferation (8). However, none of the intrinsic negative regulators of CD11b+Gr1+ MDSC maturation and function has been identified so far.

Microenvironments play an important role in the induction of CD11b+Gr1+ MDSC differentiation, but the intrinsic molecular mechanisms for controlling CD11b+Gr1+ MDSC differentiation and function are poorly understood. STAT (STAT1, STAT3, STAT5, and STAT6) and NF-κB are known to promote the differentiation of MDSCs (reviewed in Ref. 9). In addition, TGF-β is a regulatory molecule with pleiotropic effects on immune cell proliferation, differentiation, migration, and survival (10, 11) and has been shown to regulate the differentiation of myeloid cells (12–15). In the innate immune system, it controls the initiation and resolution of the inflammatory response through regulation of chemotaxis and activation of immune cells (11, 16–18). These results suggest that TGF-β signaling plays a complex role in the immune system. However, the role of TGF-β signaling in CD11b+Gr1+ MDSC maturation and function has not been determined.

In the current study, we investigate the role of Smad3 signaling in shaping the host immune response to allografts by using Smad3-deficient mice. Surprisingly, the survival of allogeneic skin or heart grafts in Smad3−/− recipients and in mice with Smad3-deficient hematopoietic cells is significantly longer compared with wild-type (WT) controls. We also show that Smad3-deficient CD11b+Gr1+ granulocytes are unable to recruit monocytes/macrophages and T cells but gain an immunosuppressive ability to inhibit the T cell response and skew T cells to Th2-type immunity in transplanted Smad3−/− mouse recipients, mainly via an NO-dependent manner. Therefore, this study offers evidence demon-
strating that Smad3 is an intrinsic factor that inhibits the differen-
tiation and immunosuppressive function of CD11b+Gr1− MDSCs in
mouse transplant models.

Materials and Methods

Mice

BALB/c, C57BL/6 (B6), SCID, C57BL/6-GFP, and Rag1−/− mice were pur-
chased from the Beijing Laboratory Animal Research Center (Beijing,
China). The Smad3+/− mice with 129sv × C57BL/6 background were pro-
vided by Dr. X. Yang (Beijing Institute of Biotechnology, Beijing,
China) (19). In this mouse line, exon 8 of the Smad3 gene is deleted.
Smad3−/− mice were backcrossed for at least six generations to B6 mice in
our laboratory and were intercrossed to produce homozygous off-
spring. The resulting progeny were screened by PCR to identify Smad3+−/−
mice and Smad3−/− littermates, which were used as WT control mice. DO11.10 mice,
which express a transgenic TCR that recognizes OVA 323–339 pep-
tide (20), were provided by the Model Animal Research Center of
Nanjing University (Nanjing, China). DO11.10 × Smad3−/− mice were
produced in our laboratory. All mice were bred and housed in pathogen-
free conditions, and all experimental procedures were in accordance with
the Institution Guidelines for the Care and Use of Laboratory Animals.

Skin and heart transplantation and histologic examination

Skin and heart grafts from BALB/c mice were transplanted into recipients
as described previously (21–24). For skin transplantation, erythema, edema,
and hair loss were considered early signs of rejection, whereas ulceration,
progressive shrinkage, and desquamation were considered to be the end
point of rejection (25). Photographs were taken daily with a digital camera
(Canon Powereshot A640; Canon, Tokyo, Japan) until the graft was rejected
completely. For heart transplantation, undetectable heart impulses for two
consecutive days were considered rejection (21). The skin grafts were
removed at the indicated time points and rinsed in cold PBS, placed in
OCT compound, and immediately frozen in liquid nitrogen for histo-
pathologic examination. Sections (4–6 μm) were fixed in 4% parafo-
maldehyde and stained with H&E for assessment of cellular infiltration.

Detection of anti-donor Abs in serum

Before transplantation (day 0) and after transplantation at indicated time
points, sera from recipients were collected and frozen at −80˚C. The IgG
isotype of anti-donor alloreactive Abs in sera were measured by flow
cytometry using a previously described technique (26, 27). Briefly, 5 × 10^6
BALB/c splenocytes were used as target cells and incubated for 30 min at
4˚C with either negative control serum (diluted 1:10) or with the recip-
ient’s serum (diluted 1:10). Then, the cells were washed three times and
incubated with optimal concentrations of FITC-conjugated goat-anti-
nouse IgG, IgG1, IgG2b, and IgG2c Abs (Santa Cruz Biotechnology) for
30 min at 4˚C in the dark. Samples were assayed using a Beckman Coulter
Epics XL benchtop flow cytometer (FCM; Beckman Coulter) and were
analyzed using FlowJo (Tree Star, Ashland, OR) software. Results were
exported as the mean fluorescence intensity of stained cells subtracted
by the mean fluorescence intensity of cells incubated with negative control
serum and FITC-labeled secondary Abs.

Bone marrow reconstitution

A total of 2 × 10^7 bone marrow cells (BMCs) from WT or Smad3−/− mice
were injected into C57BL/6-GFP mice or SCID mice lethally irradiated 4 h
previously with 8.0 Gy radiation (60Co source). Recipients were tested for
molecular Probes, Eugene, OR) and injected i.v. into syngeneic BALB/c mice.

In vivo T cell migration assay

To detect neutrophil and macrophage migration in vivo, 1 ml sterile 3%
thioglycollate (TG; warmed to room temperature) was injected i.p. into WT
or Smad3−/− mice. Ten hrs after TG injection, peritoneal cells were har-
vested and analyzed by FCM. To compare WT with Smad3−/− neutrophil
migration in vivo, sorted WT CD11b+Gr1+ cells were transfected with
PKH26 (Sigma-Aldrich) and Smad3−/− cells were labeled with CFSE (Mole-
cular Probes). A total of 5 × 10^6 PKH-26-labeled WT CD11b+Gr1+ cells mixed
with 5 × 10^5 CFSE-labeled Smad3−/− CD11b+Gr1+ cells were injected i.v.
into WT mice. The recipients then received 1 ml 3% TG treatment over
24 h. Peritoneal cells were then collected, and the infiltrated WT and
Smad3−/− neutrophils were analyzed by FCM. The following protocol was
used to prepare the 3% TG solution: 30 g of TG powder in 1000 ml
neutralized water was autoclaved for 20 min at 121˚C. The sterile 3% TG
was protected from light and was “aged” at room temperature for at least
1 mo to ensure formation of advanced glycation end products (28).

TNF-α, IL-6, and iNOS production by peritoneal exudate
macrophages

WT and Smad3−/− peritoneal exudate macrophages (PEMs) were iso-
lated as described previously (29, 30). A total of 5 × 10^5 PEMs were stimu-
lated with 50 ng/ml IFN-γ (PeproTech) and 1 μg/ml LPS (Escherichia coli III:
B4; Sigma-Aldrich) in 24-well plates for 24 h at 37˚C and 5% CO2. To
detect intracellular TNF-α and IL-6 by FCM, 1 μl/ml brefeldin A (BD
GolgiPlug; BD Biosciences) was added during the last 8 h of culture (29).
TNF-α, IL-6, and iNOS mRNA was measured by real-time PCR.

Phagocytosis of cRBCs by PEMs in vitro

Phagocytosis of chicken RBCs (cRBCs) by CD11b+Gr1− PEMs was
detected in vitro as described previously (31). Single-cell suspension of
cRBCs was freshly obtained. After two washes with PBS, 1 × 10^7 cRBCs/
mouse were labeled with 5.0 μM CFSE (Molecular Probes) for 15 min at 37˚C.
These cells were then washed thoroughly and resuspended at a concentra-
tion of 1 × 10^7/ml. Cell viability was determined by trypan blue exclusion.
Cell viability was usually >95%. A total of 1 × 10^7 PEMs were co-
cultured with CFSE-labeled cRBCs at a ratio of 1:10 for 2–2.5 h at 37˚C and
5% CO2. PEMs were then treated with 2% gelatin (Sigma-Aldrich) (32). After 2–2.5 h, unengulfed cRBCs were removed by aspirating
supernatants and gently washing with cold PBS. Adherent cells were har-
vested with 5 ml EDTA (Sigma-Aldrich) in ice-cold PBS (pH 7.2) and

Downloaded from http://www.jimmunol.org/ on May 29, 2017
readjusted. Cells were then stained with PE-anti-F4/80, and the percentage of phagocytosed F4/80+ cells was determined using FCM.

FCM analysis
Draining lymph node (DLN) cells or spleen cells were prepared as described previously (33). Cell preparations were stained with optimized AB dilutions. For surface marker staining, the following Abs-fluorochrome combinations were used: FITC, PE, or PE-Cy5-anti-mouse (m)CD4 (RM4-5), PE or FITC-anti-mCD8 (Y4.1), FITC or PE-anti-mLy6G (1A8), FITC or PE-anti-mLy6C (AL-21), FITC or PE-anti-mF4/80 (BM8), PE-anti-mCD11c (HL3), PE-anti-mNCXR2 (242216), FITC-anti-mCD62L (MEL-14), FITC-anti-mCD44 (IM7), and Alexa Fluor 488-anti-mCD115 (AF598). For intracellular staining, FITC-anti-miNOS (6/iNOS/NOS TypeII), and PE or PE-Cy5-anti-mGr1 (RB6-8C5), FITC or PE-anti-mLy6G (1A8), FITC or PE-anti-mCD11b (M1/70), PE or PE-CD11b-Gr1+ cells (RB6-8C5) were used. Then, cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD Pharmingen). They were then stained extracellularly with PE-anti-miF4/80 (X5G1.2) or PE-anti-mIL-4 (10G9.2) or PE-anti-mCD11b (M1/70) or PE-anti-mCD123 (53–6.7) and PE-anti-mTCRβ (H57–597), PE-KJ1–26, PE-anti-mTCRδ (RB5.5; RORα), PE-anti-mTCRε (RB5.10; iNOS), PE-anti-mTCRγ (RB5.2; IL-17), PE-anti-mTCRδ (RB5.10; iNOS), PE-anti-CD123 (53–6.7). Intracellular NO production assay
To deplete CD11b+Gr1+ cells in vivo, 0.25 mg depleting anti–Gr-1 mAb (RB6-8C5) was injected i.p. into recipients at days −1 and 3 after skin transplantation. To detect immunosuppression of CD11b+Gr1+ cells in vivo, WT and Smad3−/− mice were transplanted with BALB/c skin grafts. Seven days later, CD11b+Gr1+ cells (3 × 10^6) from the spleens of WT and Smad3−/− mice were sorted and injected i.v. into syngeneic B6 mice. One day after adoptive transfer, these mice were grafted with BALB/c skin. Skin grafts were followed daily.

In vivo and in vitro functional assay of CD11b+Gr1+ cells
To deplete CD11b+Gr1+ cells in vivo, 0.25 mg depleting anti–Gr-1 mAb (RB6-8C5) was administered i.p. into recipients at days −1 and 3 after skin transplantation. To detect immunosuppression of CD11b+Gr1+ cells in vivo, WT and Smad3−/− mice were transplanted with BALB/c skin grafts. Seven days later, CD11b+Gr1+ cells (3 × 10^6) from the spleens of WT and Smad3−/− mice were sorted and injected i.v. into syngeneic B6 mice. One day after adoptive transfer, these mice were grafted with BALB/c skin. Skin grafts were followed daily.

For the in vitro suppression assay, sorted CD11b+Gr1+ cells from spleens of WT and Smad3−/− recipients obtained 7 d after allograft transplantation were added to the MLR system. B6 splenocytes (1 × 10^6 cells/well) were cocultured with 30 μg/ml mitomycin C-pretreated BALB/c splenocytes (1 × 10^6 cells/well) and sorted CD11b+Gr1+ cells (1 × 10^6 cells/well) for 96 h in flat-bottom 96-well plate at 37°C in 5% CO2. The culture medium consisted of RPMI 1640 medium supplemented with l-glutamine (2 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2-ME (5 × 10−4 M), and 10% FCS. The proliferation was measured using a BrdU proliferation kit (Delfia Proliferation Kit; PerkinElmer). A total of 5 mM M2-monomethyl-l-arginine (l-NMMA; Sigma-Aldrich) was added at the beginning of the culture to block NO pathways. To determine the effect of arginine on the immunosuppressive activity of Smad3−/− CD11b+Gr1+ cells, a low dose of l-arginine (2 mM) or a high dose of l-arginine (5 mM) was added to this culture system.

NO production assay
After incubating equal volumes of culture supernatants or serum (100 μl) with Greiss reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-1-naphthylethenediamine dihydrochloride in double-distilled water) at room temperature for 10 min, the absorbance at 550 nm was measured using a microplate reader (Bio-Rad). Nitrite concentrations were determined by comparing the absorbance values for the test samples to a standard curve generated by serial dilution of 0.25 mM sodium nitrite.

Induction of CD11b+Gr1+ cells from bone marrow progenitors
Bone marrow flushed from the tibia and femora of WT and Smad3−/− mice was subjected to magnetic activated cell sorting against a panel of Abs directed against lineage-committed Ags (Miltenyi Biotec). Hematopoietic stem and progenitor (Lin−) cells were collected and plated at 2 × 10^5 cells/ml and incubated with recombinant murine GM-CSF (20 ng/ml; PeproTech) for 5 days in DMEM with L-glutamine (2 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), and 10% FCS. To detect iNOS expression in induced CD11b+Gr1+ cells by FCM, the 5-d cultured cells were stained with PE-anti-F4/80, and the percentage of F4/80+ cells was determined using FCM.

In vitro assays measuring the effect of TGF-β1 on NO production
To determine the effect of TGF-β1 on NO production in WT CD11b+Gr1+ cells, 2 × 10^5 sorted CD11b+Gr1+ cells isolated from spleens of WT mice 7 d after allograft transplantation were cultured with LPS (100 ng/ml), TGF-β1 (5 ng/ml; R&D Systems), or TGF-β1 neutralizing Abs (2 μg/ml, clone 1D11; R&D Systems) (36) in 96-well plates for 6 h. Then, 100 μl culture supernatant was used to detect NO. Intracellular iNOS expression was analyzed by FCM (36).
Results

Delayed allograft rejection in mice with Smad3-deficient hematopoietic cells

To understand the role of Smad3-mediated pathways in the immune response to allograft, we first observed skin allograft survival in Smad3-deficient mice. On the basis of the anti-inflammatory effects of TGF-β, we expected Smad3-deficient mice to show enhanced immunity against allografts. Surprisingly, the MST of BALB/c (H-2d) skin allograft was significantly longer in Smad3−/− mice (B6 background, H-2b, MST = 11 d, n = 15) compared with WT littermates (MST = 7 d, n = 15, p < 0.001; Fig. 1A). As shown in Fig. 1B, from day 7 to 11, alloskin grafts on WT recipients showed progressive loss of hair, dermal necrosis and scab formation. However, the graft on Smad3−/− recipients showed normal gross appearance and hair growth. Histologic examination of skin allograft revealed mild immune cell infiltration in the derma of skin grafts in Smad3−/− recipients at days 2 and 7 after grafting compared with skin grafts in WT recipients, which showed moderate infiltration and necrosis at day 7 (Fig. 1C).

To identify whether Smad3 intrinsically regulates immune cells derived from the hematopoietic compartment or indirectly impairs the rejection response by regulating peripheral tissues and microenvironments, we transplanted BMCs from either WT or Smad3−/− mice into lethally irradiated syngeneic GFP-B6 mice or SCID mice to establish full chimeras. Eight weeks after bone marrow transplant, we grafted allogeneic BALB/c skin on these reconstituted mice. We found that lethally irradiated GFP-B6 and SCID mice reconstituted with Smad3−/− BMCs rejected the allografts with a MST of 15 d, which was significantly longer than the MST of 11 d in mice reconstituted with WT BMCs (p < 0.001, n = 6; Fig. 1D, 1E). Consistent with these results, allogeneic BALB/c heart grafts survived significantly longer in Smad3−/− BMC→B6 chimera recipients than WT BMC→B6 chimera recipients (p < 0.01, n = 5; Fig. 1F). Thus, Smad3 deficiency in hematopoietic cells decreases the immune response against allografts in an intrinsic manner.

The Th2 immune system is preferentially activated in response to allografts in Smad3-deficient mouse recipients

To determine the intensity of humoral and Th1/Th2 immune responses to allografts in Smad3-deficient recipients of alloskin grafts, we measured the levels of anti-donor IgG subclasses in the serum with FCM assays, as previously described (37), and cytokines, including IL-6, IL-17, IFN-γ, TNF-α, IL-4, and IL-10, with CBA. The level of total anti-donor IgG in Smad3−/− recipients was significantly lower than WT recipients 2 wk posttransplantation (p < 0.001; Fig. 2A). Similarly, anti-donor IgG1, IgG2c, and IgG2b levels were lower in Smad3−/− recipients. In parallel with this observation, significantly less activated/memory CD62LlowCD4+CD44+ cells were detected in skin-grafted Smad3−/− mice compared with WT recipients (p < 0.05; Supplemental Fig. 1). Smad3−/− recipients produced less IFN-γ and a remarkably higher quantity of IL-4 and IL-10 compared with WT recipients (p < 0.001, n = 5; Fig. 2B). IL-6, IL-17, and TNF-α levels were not different in Smad3-deficient recipients and WT recipients, except for the enhanced IL-6 level in WT recipients at day 7 (Fig. 2B). In addition, enhanced IL-4 and IL-10 mRNA expression were detected in splenocytes of Smad3−/− recipients by real-time PCR assays 7 d after grafting (data not shown). TGF-β1 mRNA expression in splenocytes of Smad3−/− recipients showed a slight but significant decrease compared with WT mice (data not shown).

Notably, expression of the Th1-specific transcription factor, T-bet, was significantly decreased, and expression of the Th2-specific transcription factor, GATA3, was markedly increased in splenocytes of Smad3−/− recipients (p < 0.001 versus WT mice; Fig. 2C). Th17-related retinoic acid-related orphan receptor γT expression did not show detectable alteration, and CD4+CD25+ Treg cells were detected in skin-grafted Smad3−/− recipients (p < 0.05; Fig. 2C). Th17-related retinoic acid-related orphan receptor γT expression did not show detectable alteration, and CD4+CD25+ Treg cells were detected in skin-grafted Smad3−/− recipients (p < 0.05; Fig. 2C).

The initiation of antiallograft immunity is known to occur in secondary lymphoid tissues where recipient T cells are activated, undergo clonal expansion, and differentiate into effector cells. In addition, CD4+ T cells activate B cell production of anti-donor autoantibodies. BALB/c skin or heart grafts. (A) Alloskin graft rejection in Smad3−/− recipients was significantly more delayed compared with WT recipients. (B) Macroscopic pictures of alloskin grafts at different time points. (C) Histologic changes in alloskin grafts at days 2 and 7. H&E staining was performed for each sample. (D) B6 mice reconstituted with Smad3−/− BMCs rejected alloskin grafts more slowly compared with B6 mice with full WT bone marrow chimera. (E) SCID mice reconstituted with Smad3−/− BMCs rejected alloskin grafts more slowly compared with SCID mice with full WT bone marrow chimera. (F) Alloheart graft rejection was significantly more delayed in Smad3−/− recipients than in WT recipients. **p < 0.01, ***p < 0.001 for comparisons between indicated groups.

FIGURE 1. Significantly delayed allograft rejection in Smad3−/− recipients. Age-matched WT and Smad3−/− mice were transplanted with allogeneic BALB/c skin or heart grafts. (A) Alloskin graft rejection in Smad3−/− recipients was significantly more delayed compared with WT recipients. (B) Macroscopic pictures of alloskin grafts at different time points. (C) Histologic changes in alloskin grafts at days 2 and 7. H&E staining was performed for each sample. (D) B6 mice reconstituted with Smad3−/− BMCs rejected alloskin grafts more slowly compared with B6 mice with full WT bone marrow chimera. (E) SCID mice reconstituted with Smad3−/− BMCs rejected alloskin grafts more slowly compared with SCID mice with full WT bone marrow chimera. (F) Alloheart graft rejection was significantly more delayed in Smad3−/− recipients than in WT recipients. **p < 0.01, ***p < 0.001 for comparisons between indicated groups.
Abs in transplant models. Thus, we analyzed the cells from the DLNs and spleen. We found that the percentage of CD4+Foxp3+ Tregs were slightly increased, whereas the percentage of CD8+ T cells and CD19+ B cells were decreased in spleens and DLN of Smad32/−/− mice at day 14 after transplantation (data not shown). Importantly, the percentage of IL-2+CD4+ cells and IFN-γ+CD4+ cells in CD4+ T cells as well as their cell numbers were significantly decreased in the spleens of Smad32/−/− recipients 7 d after transplantation (p, 0.001; Fig. 2D). The cytotoxic CD8+IFN-γ+ T cells were also decreased in Smad32/−/− recipients compared with those in WT recipients (p, 0.001; Fig. 2E). In contrast, IL-4+CD4+ cells and IL-10+CD4+ cells in Smad32/−/− recipients were increased in percentage and cell number (p, 0.001; Fig. 2F).

Therefore, these data collectively indicate that host immunity of Smad32/−/− recipients promotes a skewed Th2-type immune response after alloskin grafting.

Smad3-deficient T cells respond efficiently to alloskin grafts

T cells play a central role in alloskin graft rejection. To see whether intrinsic impairment of T cell function by Smad3 can explain delayed alloskin graft rejection in Smad3-deficient recipients, we first confirmed the potential direct effects of Smad3 on T cell function in vitro and in vivo. T cells showed normal development in Smad3-deficient mice, as determined by the normal thymocyte subset distribution and Vb family expression (Ref. 19; data not shown). Smad3-deficient T cells proliferated with Con A stimulation in a similar manner to WT control cells (Fig. 3A). However, TGF-β inhibition on Con A-induced T cell proliferation was less efficient in Smad3-deficient T cells compared with WT control cells (Fig. 3A), consistent with a previous report (19). The percentages of Foxp3+ cells in the freshly isolated naive CD4+ cells (CD4+CD62LhighCD25−) from either WT or Smad32/−/− mice were, 0.1% as determined by FCM (Fig. 3B). However, after CD4+CD25+ Treg induction from naive CD4+CD62LhighCD25− cells with TGF-β in vitro, significantly fewer CD4+CD25+Tregs were induced from Smad3-deficient naive CD4+ T cells compared with WT naive T cells (Fig. 3B). IFN-γ production in isolated Smad3-deficient naive CD4+ T cells and WT T cells was similar after stimulation with ionomycin/PMA (Fig. 3C). We also investigated the ability of Smad3-deficient T cells to migrate by using Smad3-deficient CD4+ T cells with a transgenic TCR (referred to as Smad32/−/−KJ1-26+CD4+ T cells), which is recognized by KJ1-26 mAb. We adoptively transferred either CFSE-labeled WT CD4+ T cells or Smad32/−/−KJ1-26+CD4+ T cells into syngeneic BALB/c
mice. After adoptive transfer, mice were immunized with OVA in CFA. Percentages and cell numbers in DLN were detected 36 h after immunization. The percentage and cell number of Smad3-/- T cells were similar to WT T cells after stimulation with ionomycin/PMA. (D-F) Cell migration of adoptively transferred Smad3-/- KJ1-26+ T cells was identical to WT KJ1-26+ T cells 36 h after OVA immunization. (G) Adoptively transferred Smad3-/- T cells rejected alloskin grafts as efficiently as WT T cells in Rag1-/- recipients. (H) Adoptively transferred Smad3-/- CD4+ T cells rejected alloskin grafts as efficiently as WT CD4+ T cells in Rag1-/- recipients. (I and J) Smad3-/- macrophages demonstrated normal phagocytosis of cRBCs in vitro. (K) Increased NO production by Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. (L) Increased TNF-α but not IL-6 protein expression by Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. (M) Increased TNF-α and iNOS mRNA and unchanged IL-6 mRNA expression in Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. Data are presented as mean ± SD (n = 5), which represent one of two independent experiments with similar results. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control WT mice.

FIGURE 3. The direct effects of Smad3 on T cells and macrophages in vitro and in vivo. (A) Sorted Smad3-/- T cells were resistant to TGF-β-mediated immunosuppression in vitro, as determined by cell proliferation stimulated by Con A. (B) Sorted naive Smad3-/- T cells were resistant to TGF-β–induced CD4+CD25+Foxp3+ Treg in Tregs in vitro. (C) IFN-γ expression in Smad3-/- CD4+ T cells was similar to WT cells after stimulation with ionomycin/PMA. (D-F) Cell migration of adoptively transferred Smad3-/- KJ1-26+ T cells was identical to WT KJ1-26+ T cells 36 h after OVA immunization. (G) Adoptively transferred Smad3-/- T cells rejected alloskin grafts as efficiently as WT T cells in Rag1-/- recipients. (H) Adoptively transferred Smad3-/- CD4+ T cells rejected alloskin grafts as efficiently as WT CD4+ T cells in Rag1-/- recipients. (I and J) Smad3-/- macrophages demonstrated normal phagocytosis of cRBCs in vitro. (K) Increased NO production by Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. (L) Increased TNF-α but not IL-6 protein expression by Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. (M) Increased TNF-α and iNOS mRNA and unchanged IL-6 mRNA expression in Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. Data are presented as mean ± SD (n = 5), which represent one of two independent experiments with similar results. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control WT mice.

Increased TNF-α and iNOS mRNA and unchanged IL-6 mRNA expression in Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. (M) Increased TNF-α and iNOS mRNA and unchanged IL-6 mRNA expression in Smad3-/- macrophages after stimulation with LPS + IFN-γ, compared with WT macrophages. Data are presented as mean ± SD (n = 5), which represent one of two independent experiments with similar results. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the control WT mice.
strated a somewhat higher inflammatory response than WT macrophages in vitro.

**Impaired immune cell infiltration in allografts of Smad3-deficient recipients**

To gain insight into the changes occurring in local graft immune cell subsets and determine the reasons for delayed graft rejection in Smad3-deficient mice, we characterized the cells infiltrating the alloskin graft by FCM analysis at certain time points. We found that the infiltrating leukocyte population consisted mainly of neutrophils (CD11b^+Ly6G^+), inflammatory monocytes (F4/80^+Ly6C^+), CD4^+ T cells and CD8^+ T cells. NK cells were also present but in smaller proportions (data not shown). However, Smad3^-/- recipients exhibited a significantly higher CD11b^+Ly6G^+ granulocyte infiltration and a clear reduction in macrophage and T cell populations in skin grafts compared with WT recipients (p < 0.001; Fig. 4A, 4B). Furthermore, real-time PCR assays 4 d after grafting showed that the expression of CXCL1 and CXCL2, chemokines important for neutrophil recruitment, were significantly increased, whereas the expression of chemokines central to T cell recruitment, CCL3 (MIP-1a), MCP-1, and RANTES, were markedly lower in skin grafts in Smad3^-/- mouse recipients compared with WT mice (p < 0.001; Fig. 4C). Allogeneic Smad3^-/- skin grafts in BALB/c recipients were rejected as efficiently as WT skin grafts and showed identical innate immune cell infiltration 3 and 7 d after skin grafting (data not shown). These results indicate that Smad3 deficiency in the donor organ does not affect graft survival and immune cell infiltration in allografts. To further determine whether immune cell infiltration is impaired in Smad3-deficient mouse recipients, we performed immune cell recruitment assays in vivo. After inducing peritonitis with 3% TG, the major infiltrating cells were neutrophils during the early time period (4–6 h) and other cells, including macrophages and T cells, during the later time period (>10 h) (Ref. 39; data not shown). Significantly more neutrophils were recruited into the peritoneal cavities of Smad3^-/- mice in the early stage (4 h; data not shown) and later phase (10 h) (p < 0.001; Fig. 4D, 4E). However, 10 h after induction of peritonitis, low levels of CD11b^+ F4/80^+ macrophages, CD4^+ T cells, CD8^+ T cells, and B cells were detected in the peritoneal cavity of Smad3-deficient mice but still lower than levels found in WT mice (p < 0.001; Fig. 4F–I).

To determine whether Smad3^-/-CD11b^+Gr1^+ cells are more sensitive to chemokines, we compared cell migration of cotransferred PKH26-labeled Smad3^-/-CD11b^+Gr1^+ cells and CFSE-labeled WT CD11b^+Gr1^+ cells in the TG-induced peritonitis model, as described in Materials and Methods. Nearly twice as many Smad3^-/- cells migrated into the peritoneal cavity compared with WT cells (p < 0.001; Fig. 4J). To determine whether

![FIGURE 4](http://www.jimmunol.org/)
differences in sensitivity to cell death accounts for this finding, we measured cell death in freshly isolated and cultured neutrophils. Cell death was similar in Smad3−/− and WT CD11b+Gr1+ cells freshly isolated from the TG-induced peritonitis model, as determined by Annexin V and PI staining (Supplemental Fig. 3A). However, Smad3−/− CD11b+Gr1+ cells cultured with 100 ng/ml LPS for 6 h showed less cell death (p < 0.01; Supplemental Fig. 3B). In addition, after isolated CD11b+Gr1+ cells were stimulated with LPS, significantly more CXCL1 and CXCL2, which are important for neutrophil migration, were expressed by Smad3−/− CD11b+Gr1+ cells compared with WT CD11b+Gr1+ cells (Supplemental Fig. 4). Thus, Smad3-deficient neutrophils are hypersensitive to chemokine attraction and somewhat resistant to cell death but are deficient in subsequent recruitment of other immune cells, including macrophages and T cells.

Smad3-deficient CD11b+Gr1+ myeloid cells prevent allograft rejection

After observing increased CD11b+Ly6G+ myeloid cells in skin grafts, we monitored the presence of CD11b+Gr1+ myeloid cells in the spleen, DLN, and bone marrow in mice at certain time points post skin transplantation. We found that the levels of CD11b+Gr1+ myeloid cells were slightly higher in naive Smad3−/− mice compared with WT mice (day 0; Fig. 5A). More importantly, the percentage of CD11b+Gr1+ cells increased dramatically, up to 2-fold or more, at day 7 in the spleen and DLNs of Smad3−/− mice. This increase was significantly higher than WT mice (p < 0.001; Fig. 5A, 5B). Surprisingly, splenic CD11b+Gr1+ cells of skin-grafted Smad3−/− mice expressed high levels of CXCR2, CD62L, and CD115 molecules (Fig. 5C), which are correlated with the phenotype of MDSCs (reviewed in Refs. 40 and 6). CD11b+ Gr1+ MDSCs are known to consist of two major subsets: granulocytic CD11b+Ly6Cmed and monocytic CD11b+Ly6Chigh cells (40). We therefore assayed these two subsets in graft-bearing WT and Smad3-deficient mice using anti-Ly6C and anti-CD11b mAbs. The proportion of CD11b+Ly6Cmed and CD11b+Ly6Chigh cells was substantially higher in spleens of Smad3-deficient recipients compared with WT recipients (p < 0.001; Fig. 5D), indicating that granulocytic and monocytic cells increase equally in Smad3-deficient recipients. We then examined whether these induced CD11b+Gr1+ cells in skin-transplanted Smad3−/− mice act as immune suppressors, as described for MDSCs (reviewed in Ref. 6). CD11b+Gr1+ cells isolated from spleens of skin-grafted Smad3−/− mice significantly inhibited CD4+ T cell proliferation in MLR assays (p < 0.001; Fig. 5E). However, CD11b+Gr1+ cells from bone marrow of Smad3−/− mice and from bone marrow or spleens of WT mice did not show any detectable immunosuppressive activity (Fig. 5E). To determine whether the CD11b+Gr1+ cells play a protective role in allo-skin graft rejection in Smad3−/− recipients, we depleted these cells by injecting anti-Gr1 mAb RB6-8C5 twice before and after skin grafting, as described previously (41). Efficient depletion of CD11b+Gr1+ cells was achieved in these mice as evidenced by FCM (data not shown). Depletion of Gr1+ cells in WT recipients did not significantly change allo-skin graft survival time (Fig. 5F). However, depletion Gr1+ cells in Smad3−/− recipients clearly reversed the prolonged allograft survival time (MST in Smad3−/− recipients: 17 d versus MST in Gr1-depleted Smad3−/− recipients: 13 d, p < 0.001, n = 5; Fig. 5F). Importantly, adoptive transfer of the sorted CD11b+Gr1+ cells from skin-grafted Smad3−/− mice into syngeneic WT recipients significantly pro-

**FIGURE 5.** CD11b+Gr1+ cells in skin-grafted Smad3−/− mice are capable of immunosuppression in vitro and in vivo. (A) Significantly more CD11b+Gr1+ cells were found in spleens of skin-grafted Smad3−/− mice. (B) Significantly more CD11b+Gr1+ cells were found in DLNs of skin-grafted Smad3−/− mice. (C) CXCR2, CD62L, CD44, and CD115 expression in WT and Smad3−/− CD11b+Gr1+ cells after skin grafting. (D) Significantly higher percentage of CD11b+Ly6Cmed cells and CD11b+Ly6Cmed cells in spleens of skin-grafted Smad3−/− mice. (E) Isolated CD11b+Gr1+ cells from skin-grafted Smad3−/− mice significantly inhibited T effector cell response to allogeneic stimulator cells in vitro compared with WT cells. Assays were performed as described in Materials and Methods. The white and black bars refer to CD11b+Gr1+ cells isolated from WT and SMAD3−/− mice, respectively. Data are presented as mean ± SD (n = 5). (F) Depleting Gr1+ cells in Smad3−/− mice with mAb (RB6-8C5) significantly accelerated alloskin graft rejection. Five mice were assayed in each group. (G) Adoptive transfer of CD11b+Gr1+ cells from Smad3−/− mice significantly delayed alloskin graft rejection in syngeneic mice. A total of 1 × 106 CD11b+ Gr1+ cells isolated either from Smad3−/− mice or from WT mice were transferred into syngeneic B6 mice via i.v. injection on day −1. Alloskin grafts were transplanted on day 0, and graft survival was followed daily. Five mice were studied in each group. *p < 0.05, **p < 0.01, ***p < 0.001 for comparisons between indicated groups.
The immunosuppressive ability of Smad3-deficient CD11b+Gr1+ myeloid cells is mediated mainly by NO.

A previous report indicated that under immune stress CD11b+Gr1+ MDSCs accumulate in lymphoid organs where they inhibit T and B cell function via upregulation of NO production (42). We thus measured the NO levels in sera 7 d after skin transplantation and found that the average NO level was greatly higher in Smad3−/− recipients compared with WT mice (12.7 ± 1.1 μM in Smad3−/− mice versus 3.4 ± 0.5 μM in WT mice, p < 0.001; Fig. 6A). Consistently, the iNOS protein expression was also significantly higher in Smad3-deficient CD11b+Gr1+ cells compared with WT recipients, as detected by intracellular FCM assays (p < 0.001; Fig. 6B). Furthermore, the iNOS mRNA level in the spleens of Smad3−/− mice 7 d after skin grafting was significantly higher to levels almost four times greater than WT recipients, whereas arginase mRNA expression was lower, as detected by real-time PCR (p < 0.001; Fig. 6C). To determine whether NO production is essential for Smad3-deficient CD11b+Gr1+ immunosuppressive function, we blocked NO production by adding a specific iNOS inhibitor, L-NMMA (5 mM was used, consistent with a previous report; Ref. 43), into the in vitro function assay system, as described in Materials and Methods. L-NMMA significantly reduced NO production almost to the baseline (Fig. 6D) and efficiently blocked the immunosuppressive effects of Smad3-deficient CD11b+Gr1+ granulocytes on T cell response to alloantigens in MLR assays (p < 0.001; Fig. 6E).

NO is produced in a reaction catalyzed by iNOS in which arginine is converted into citrulline and NO. To determine whether arginine deprivation caused by increased iNOS contributes to the immunosuppressive effect of CD11b+Gr1+ cells on T cell response, we added l-arginine (2 or 5 mM) to the culture system. Arginine supplementation did not significantly reverse the inhibitory effects of Smad3−/− CD11b+Gr1+ cells on T cell proliferation (Fig. 6F), indicating that arginine depletion caused by increased iNOS activity in Smad3−/− CD11b+Gr1+ cells is unlikely to be the key reason for immunosuppression. Thus, NO is the major mediator by which Smad3-deficient CD11b+Gr1+ MDSCs suppress the immune response.

CD11b+Gr1+ cells are also known to produce TGF-β (44), and TGF-β has the ability to inhibit production of iNOS in many cells (45–47). To determine whether TGF-β inhibits the immunosuppressive function of CD11b+Gr1+ cells by decreasing iNOS production, we isolated CD11b+Gr1+ cells from WT hosts and examined whether they acquired suppressive function after TGF-β

FIGURE 6. The immunosuppressive ability of CD11b+Gr1+ cells from skin-grafted Smad3−/− mice is mediated by the NO pathway. (A) Significantly higher NO levels in sera of skin-grafted Smad3−/− mice compared with WT recipients 7 d after skin grafting. (B) Gated CD11b+Gr1+ cells from skin-grafted Smad3−/− mice expressed more iNOS 7 d after skin grafting. (C) More iNOS mRNA and less Arg1 mRNA in CD11b+Gr1+ cells from skin-grafted Smad3−/− mice 7 d after skin grafting. (D) L-NMMA markedly inhibited in vitro NO production in Smad3−/− CD11b+Gr1+ cells. (E) Blocking NO production significantly decreased the inhibitory ability of Smad3−/− CD11b+Gr1+ cells. Data are shown as mean ± SD (n = 3), which represent one of two independent experiments with similar results. (F) Adding arginine failed to change the inhibitory effect of Smad3−/− CD11b+Gr1+ cells on T cell proliferation. Data are shown as mean ± SD (n = 3). (G) Adding TGF-β (5 ng/ml) or neutralization of TGF-β using anti–TGF-β mAb (2 μg/ml) significantly altered in vitro NO production in WT CD11b+Gr1+ cells. Data are shown as mean ± SD (n = 3). (H) In the presence of TGF-β (5 ng/ml), WT CD11b+Gr1+ cells inhibited T effector cell proliferation. More CD11b+Gr1+ cells in bone marrow of Smad3−/− mice after alloskin grafting (n = 5). (J) More CD11b+Gr1+ cells were induced after myeloid precursors isolated from Smad3−/− mice were cultured with GM-CSF (20 ng/ml). (K) More CD11b+Gr1+ cells, which were induced from Smad3−/− myeloid precursors, produced NO after they were stimulated with 100 ng/ml LPS for 4 h. Data are shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 for comparisons between indicated groups.
function was blocked with neutralizing anti–TGF-β mAb in the culture system. TGF-β neutralization did increase NO production in isolated WT CD11b+Gr1+ cells in the culture system (p < 0.05; Fig. 6G), whereas adding exogenous TGF-β (5 ng/ml) inhibited NO production in WT CD11b+Gr1+ cells (p > 0.01; Fig. 6G; data not shown). Interestingly, after blocking TGF-β signaling in a coculture system, WT CD11b+Gr1+ cells displayed significant suppression of T cell proliferation (p < 0.001; Fig. 6H). These data indicate that TGF-β modulates CD11b+Gr1+ cell function.

Seven days after alloskin grafting, more CD11b+Gr1+ cells were detected in the bone marrow of Smad3−/− recipients than WT recipients (p < 0.01; Fig. 6I). To access whether Smad3-deficient bone marrow myeloid progenitors are more sensitive to GM-CSF with respect to MDSC differentiation, we cultured the sorted WT and Smad3−/− bone marrow progenitor cells in the presence of GM-CSF. More of the Smad3−/− myeloid progenitor cells differentiated into CD11b+Gr1+ cells and iNOS+CD11b+Gr1+ cells (p < 0.01; Fig. 6J, 6K). These data suggest that Smad3−/− myeloid progenitor cells may be susceptible to MDSC differentiation in the presence of GM-CSF.

Discussion

Our study demonstrates that Smad3 deficiency in hematopoietic cells causes a significantly delayed allograft rejection in mice. The decreased immunity against allografts is due to increased production of immunosuppressive CD11b+Gr1+ MDSCs, which is induced by Smad3 deficiency in transplanted mouse recipients. The Smad3-deficient CD11b+Gr1+ MDSCs significantly inhibit T cell response to alloantigens, mainly through the NO pathway. Thus, we conclude that Smad3 is an intrinsic inhibitor of immunosuppressive CD11b+Gr1+ MDSC differentiation and function in mice transplanted with allografts.

The immunosuppressive cytokine TGF-β controls immune responses and maintains immune homeostasis through its impact on the proliferation, differentiation, and survival of multiple immune cell lineages. For instance, TGF-β markedly and directly suppresses both the clonal expansion of CD8+ T cells and CD8+ T cell cytotoxicity in vivo (48). TGF-β also inhibits Th1 gene expression in CD4+ T cells in a Smad3-dependent manner (49). As another example, TGF-β, coordinating with IL-21, induces Foxp3 expression and generates Tregs (50). TGF-β, together with IL-6, also induces the lineage-specific differentiation of Th17 cells, a newly defined proinflammatory Th cell population (51, 52). Smad3−/− T cells produce abundant Th2-type cytokines (53). These effects have also been demonstrated clearly by genetic deletion or attenuation of TGF-β signaling (11). Consistent with these results, our studies and others have shown that deletion of Smad3-dependent TGF-β signaling in T cells promotes severe graft-versus-host disease (our unpublished data and Ref. 38). In our investigation, Smad3-deficient CD4+CD25− T cells were resistant to TGF-β-induced differentiation into CD4+CD25+ Tregs in vitro, as expected. We also anticipated that Smad3 deficiency in T cells would intrinsically increase Th1 cell production and decrease CD4+CD25− Treg production, which together should accelerate allograft rejection and not delay it. Contrary to this expectation, we found increased severity of graft-versus-host disease associated with Smad3-deficient T cells and alloskin graft rejection unchanged by adoptive transfer of Smad3-deficient T cells and CD4+ T cells. These findings suggest that the delayed allograft rejection in Smad3-deficient recipients is unlikely due to the direct effects of Smad3 on T cells.

In addition to suppressing T cell function, TGF-β also has a profound impact on myeloid cell function. TGF-β can down-regulate macrophage cell function and phenotype in vitro (54–56). Our data showed that Smad3-deficient macrophages produced more of the inflammatory cytokine TNF-α. Although it is less well studied, TGF-β has also been noted to inhibit neutrophil activity, such as degranulation (57). Recent studies have suggested that blocking the TGF-β pathway increases the recruitment of neutrophils and inhibits other immune cell responses in guinea pigs with experimental tuberculous pleurisy (58). Interestingly, it is reported that blockade of TGF-β by administration of type I TGF-β receptor kinase inhibitor leads to a marked influx of CD11b+Gr1+ neutrophils with hypersegmented nuclei to tumor sites where they exert cytotoxic activity on cancer cells (59). Our present results in transplant models are somewhat consistent with these reported observations in chronic infection and cancer models. We detected significantly increased CD11b+Gr1+ granulocytes and decreased monocytes/macrophages and T cells in allografts in Smad3-deficient recipients. The inhibitory effect of Smad3 on neutrophil migration into the “alarm” location is likely cell intrinsic, as supported by the following evidence: 1) alloskin grafts were rejected slowly in WT mice constituted with Smad3-deficient hematopoietic cells; 2) TG-inducing peritonitis recruited more CD11b+Gr1+ cells to the peritoneal cavity in WT mice with Smad3-deficient hematopoietic cells than WT mice with WT hematopoietic cells; and 3) Smad3-deficient alloskin grafts were rejected as efficiently as WT alloskin grafts.

It is also noteworthy that the increased presence of CD11b+Gr1+ granulocytes in allografts and spleens in Smad3-deficient mice was associated with partial defects, such as reduced chemokine production. This result is consistent with a study using an infection model (58). In contrast, another study demonstrated that TGF-β receptor blockade resulted in an increased presence of CD11b+Gr1+ granulocytes in tumors and a hypermature phenotype (59). Our results also correspond with this study. Smad3-deficient CD11b+Gr1+ granulocytes demonstrated MDSC phenotypes, such as a high level of CD62L and CD115 expression. In addition, Smad3-deficient CD11b+Gr1+ granulocytes produced a profound quantity of NO and inhibited the T cell response to alloantigens. Depleting this cell population by administration of mAb accelerated allograft rejection in Smad3-deficient mouse recipients. Thus, our study suggests that the increased presence of Smad3-deficient CD11b+Gr1+ MDSCs is at least partially responsible for the delayed graft rejection in Smad3-deficient mice. Our data also offer evidence that the Smad3 pathway, activated by TGF-β and other factors, is a negative regulator for the differentiation and immunosuppressive function of CD11b+Gr1+ MDSCs in mice.

MDSCs represent a heterogeneous population, including monocytic MDSCs expressing CD11b+Ly6C+ and granulocytic MDSCs with CD11b+Ly6C− phenotypes (40). The involvement of MDSCs in transplantation has been demonstrated in various models (60–62). Our results in Smad3-deficient mice, which demonstrated inhibitory effects of the increased CD11b+Gr1+ MDSCs on the immunity against allografts, is consistent with these reports (60–62). These data collectively support the critical role of CD11b+Gr1+ MDSCs in preventing allograft rejection. We also suggest that the NO pathway is responsible for this effect. Smad3-deficient CD11b+Gr1+ MDSCs expressed high levels of iNOS and low levels of arginase-1. Blocking NO pathways markedly reversed the immunosuppressive effect of CD11b+Gr1+ MDSCs on the T cell response, indicating that NO is one of the major pathways by which Smad3-deficient CD11b+Gr1+ MDSCs achieve immune suppression.

To summarize, to our knowledge, we identify for the first time Smad3 as an important intrinsic factor that negatively regulates the maturation and function of the immunosuppressive CD11b+Gr1+ MDSCs. Smad3 functions in parallel with other molecules,
including STAT1, STAT3, STAT5, STAT6, and NF-κB, which positively promote the differentiation of MDSCs (reviewed in Ref. 9). Additional insight into the control of MDSCs by Sma3 will not only illuminate the fundamental molecular principles of MDSCs regulation but also facilitate the clinical application of MDSCs in treating immune disorders.

Acknowledgments
We thank Prof. David Corbin and Drs. Nicholas Nahm and Hanhan Li for editing the manuscript, Dr. Haiying Luo for review of the manuscript, Jing Wang, Yabing Liu, and Xiaqiu Liu for expert technical assistance, Qing-huan Li and Jiaxia Peng for excellent laboratory management, and Hongfei Wu for outstanding animal husbandry.

Disclosures
The authors have no financial conflicts of interest.

References


Supplementary Figure 1. Decreased activated/memory T cells in spleens of allo-skin-grafted Smad3^{-/-} mice compared to WT recipients.

The percentages and cell numbers of CD62L^{low}CD4^{+} cells and CD62L^{low}CD8^{+} cells were detected by FCM 7 days after allo-skin grafting. (A) One representation of cell staining detected by FCM. (B) Cell numbers of CD62L^{low}CD4^{+} cells and CD62L^{low}CD8^{+} cells are summarized. Data are shown as mean±SD (N=3). *P<0.05, **P<0.01 compared to the control group.
Supplementary Figure 2. Decreased cell number and activation of T cells and increased percentage and cell number of CD11b+Gr1+ cells in dLNs of DO11.10×Smad3−/− mice after immunization with OVA.

The percentage and cell number of CD4+KJ1-26+, CD4+KJ1-26+CD25+, CD4+KJ1-26+CD69+ and CD11b+Gr1+ cells in dLNs were measured 7 days after immunization with OVA. (A) Total cell number of CD4+KJ1-26+ cells and CD62LlowCD8+ cells in dLNs are summarized. (B) One representation of CD25 and CD69 staining of CD4+KJ1-26+ gated cells, as detected by FCM. (C) Total cell number of CD4+KJ1-26+CD25+ and CD4+KJ1-26+CD69+ cells in dLNs 7 days after immunization with OVA. Data are shown as mean±SD (N=3). (D) One representation of CD11b and Gr1 staining of dLN immune cells, as detected by FCM. (E) Percentage of CD11b*Gr1+ cells in dLNs 7 days after immunization with OVA. (F) Total cell number of CD11b*Gr1+ cells in dLNs 7 days after immunization with OVA. Data are shown as mean±SD (N=3). *P<0.05, **P<0.01 compared to the control group.
Supplementary Figure 3. In vitro survival of CD11b^Gr1^ cells in Smad3^−/− mice.

(A) Percentage of PI^+Annexin V^+ cells among CD11b^Gr1^ cells isolated from the peritoneal cavity of 3% TG-treated mice. (B) Percentage of PI^+Annexin V^+ cells among CD11b^Gr1^ cells after they were cultured with LPS in vitro. Data are shown as mean±SD (N=3). **P<0.01 compared to the control group.
Supplementary Figure 4. CXCL1 and CXCL2 mRNA expression in CD11b+Gr1+ cells isolated from WT and Smad3-/- mice after in vitro LPS stimulation. (A) CXCL1 mRNA expression in isolated CD11b+Gr1+ cells cultured with LPS in vitro. (B) CXCL2 mRNA expression in isolated CD11b+Gr1+ cells cultured with LPS in vitro. Data are shown as mean±SD (N=3). **P<0.01 compared to the WT mice.